Dominic J Gessler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7213334/publications.pdf

Version: 2024-02-01

933447 1125743 21 473 10 13 citations h-index g-index papers 21 21 21 775 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	GammaTile $\hat{A}^{@}$ brachytherapy in the treatment of recurrent glioblastomas. Neuro-Oncology Advances, 2022, 4, vdab185.	0.7	10
2	Canavan Disease as a Model for Gene Therapy-Mediated Myelin Repair. Frontiers in Cellular Neuroscience, 2021, 15, 661928.	3.7	11
3	Structural characterization of a novel human adeno-associated virus capsid with neurotropic properties. Nature Communications, 2020, 11, 3279.	12.8	30
4	GammaTile < sup > \hat{A}^{\otimes} < /sup > : Surgically targeted radiation therapy for glioblastomas. Future Oncology, 2020, 16, 2445-2455.	2.4	33
5	Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System. Methods in Molecular Biology, 2019, 1950, 143-163.	0.9	20
6	Transcriptome Profiling of Neovascularized Corneas Reveals miR-204 as a Multi-target Biotherapy Deliverable by rAAVs. Molecular Therapy - Nucleic Acids, 2018, 10, 349-360.	5.1	24
7	A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. Molecular Therapy - Methods and Clinical Development, 2018, 9, 234-246.	4.1	42
8	Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. Nature Biotechnology, 2018, 36, 839-842.	17.5	36
9	Adeno-associated virus serotype rh.10 displays strong muscle tropism following intraperitoneal delivery. Scientific Reports, 2017, 7, 40336.	3.3	18
10	Redirecting N-acetylaspartate metabolism in the central nervous system normalizes myelination and rescues Canavan disease. JCI Insight, 2017, 2, e90807.	5.0	49
11	58. Pushing the Limits for Canavan Gene Therapy into Adulthood: Is There an Age Limit for Gene Therapy in CNS Disorders?. Molecular Therapy, 2016, 24, S25-S26.	8.2	1
12	733. Somatically Repairing Compound Heterozygous Recessive Mutations by Chromosomal Cut-and-Paste for In Vivo Gene Therapy. Molecular Therapy, 2016, 24, S289.	8.2	0
13	157. High-Field In Vivo Neuroimaging to Determine CNS Gene Therapy Outcome and Probe Disease Pathomechanism. Molecular Therapy, 2016, 24, S61-S62.	8.2	0
14	349. The Cure of Canavan Disease: Is It a Scientific Fiction or Clinical Reality?. Molecular Therapy, 2016, 24, S140.	8.2	0
15	351. Efficacious Non-Oligodendrocyte Gene Therapy Suggests a New Dogma About CNS Compartmentalization of NAA Metabolism and Supports a Metabolic Sink Theory. Molecular Therapy, 2016, 24, S140-S141.	8.2	0
16	366. Hitting Two Birds with One Stone: How Efficacious Pre-Clinical Gene Therapy Cures Canavan Disease and Sheds Light onto the Pathomechanism. Molecular Therapy, 2016, 24, S147.	8.2	0
17	739. rAAV Delivered MicroRNA Therapeutics Towards Efficacious Treatment of Corneal Neovascularization. Molecular Therapy, 2016, 24, S291.	8.2	0
18	Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders. Methods in Molecular Biology, 2016, 1382, 429-465.	0.9	20

#	Article	IF	CITATIONS
19	586. Development of Anti-Angiogenic miRNA Therapeutics for Corneal Neovascularization. Molecular Therapy, 2015, 23, S233.	8.2	0
20	496. From Gene Therapy to Gene Enhancement: Optimized Pre-Clinical Gene Therapy Transforms Mice with the Severest Canavan Disease Phenotype Into "Supermice― Molecular Therapy, 2015, 23, S198.	8.2	0
21	Global CNS Transduction of Adult Mice by Intravenously Delivered rAAVrh.8 and rAAVrh.10 and Nonhuman Primates by rAAVrh.10. Molecular Therapy, 2014, 22, 1299-1309.	8.2	179